Everything below concerns Heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
== History == The first known reference to the dura appears in Egypt, in Case 6 of the Edwin Smith Papyrus. Hippocrates described the dura in his monograph "On Injuries of the Head" and insisted that care should be taken to keep it intact and clean. Celsus agreed, and described a method of treatment for depressed fractures. Galen was the first to describe the pia mater in humans in the second century AD.
Many governments require food manufacturers to label the energy content of their products to help consumers control their energy intake. To facilitate evaluation by consumers, food energy values (and other nutritional properties) in package labels or tables are often quoted for convenient amounts of the food, rather than per gram or kilogram; such as in "calories per serving" or "kcal per 100 g", or "kJ per package". The units vary depending on country:
In 1958, the Independent Socialist League, led by Max Shachtman, dissolved and joined the Socialist Party of America (SPA), which was founded by Eugene V. Debs. Shachtman had written that Soviet communism was a new form of class society, bureaucratic collectivism, in which the ruling class exploited and oppressed the population, and therefore he opposed the spread of communism. Shachtman argued that democratic socialists should work with labor unions and civil rights organizations to build a social democratic "realignment" of the Democratic Party. "Shachmanites" had a great amount of influence on the SPA. In its 1972 convention, the SPA changed its name to Social Democrats, USA by a vote of 73 to 34, supported by both Co-Chairmen, Bayard Rustin and Charles S. Zimmerman. This rename was meant to be "realistic". The New York Times observed that the Socialist Party had last sponsored Darlington Hoopes as its candidate for president in the 1956 election, who received only 2,121 votes, in just six states. The majority report noted that the name "party" was "misleading" because the SPA no longer sponsored presidential candidates, and also hindered recruitment of activists who participated in the Democratic Party. The name "Socialist" was replaced by "Social Democrats" because many American associated the word "socialism" with Soviet communism. The party also wished to distinguish itself from two small Marxist parties.
== Adverse effects == Adverse effects almost solely occur in humans that suffer from glucose-6-phosphate dehydrogenase deficiency. This deficiency causes a shortage of glutathione in erythrocytes and glutathione is needed for the neutralization of ROS (reactive oxygen species) created by the strongly oxidizing agent divicine. Glucose-6-phosphate dehydrogenase deficiency is a common genetic condition, with a global prevalence of approximately 4.9%, affecting over 400 million individuals worldwide. It is important to recognize that glucose-6-phosphate dehydrogenase deficiency can still be life-threatening if not promptly diagnosed and managed. Effective management often includes interventions as blood transfusions, but with appropriate care, full recovery from favism without lasting complications is the expected outcome.
Sources: en.wikipedia.org
Taiwan's migrant worker population—estimated in 2018 to be up to 660,000 in number—have reportedly faced slavery-like conditions involving sexual abuse in the domestic work sector and forced labor in fishing sectors. Taiwan is among a minority of places in the world that legally allows labor brokers to charge migrant workers for services which elsewhere are covered by employers as human resource costs. A few Taiwanese universities have reportedly tricked students from Eswatini, Uganda and Sri Lanka into forced labour at factories as payment for the university programs. Some charity groups in 2007 also insisted that foreign women—mostly from China and Southeast Asia—were being forced into prostitution, although local police in Tainan disagreed and said they deliberately came to Taiwan "to sell sex".
== Etymology == The origin of the gly- and glu- prefixes for glycols and sugars is from Ancient Greek γλυκύς glukus which means sweet. Glycérine was coined c. 1811 by Michel Eugène Chevreul to denote what was previously called "sweet principle of fat" by its discoverer Carl Wilhelm Scheele. Chevreul's term was borrowed into English c. 1838, and during the 20th century it was displaced by an 1872 term glycerol that incorporates the -ol suffix common to alcohols.
Criminologist Jane Monkton-Smith said it was particularly unusual that Norris didn't behave as if he wanted to defend himself in interviews, but instead challenged the police and acted evasively. Norris later admitted that he was trying to show how much more he knew than the police in interviews. In 2004, during the investigation, he walked into the offices of the Yorkshire Evening Post and declared that the police had "nothing on him" to reporters. Chief superintendent on the case Chris Gregg claimed that Norris's prediction of Hall's illness showed that it wasn't just a spontaneous incident where a criminal nurse at work had, for whatever reason decided to kill someone, saying "he actually premeditated this, hours before". Gregg said: "I think he was cocky; I think he was over-confident. He was showing off". A criminal psychologist stated that, despite Norris's prediction, it was unlikely that he wanted to get caught, rather that he merely wanted to demonstrate a sense of superior knowledge. Police noted that, in interviews, Norris showed no empathy for the women who had died or for their families, and claimed he couldn't remember any of the women.
Norepinephrine has been reported to exist in a wide variety of animal species, including protozoa, placozoa and cnidaria (jellyfish and related species), but not in ctenophores (comb jellies), whose nervous systems differ greatly from those of other animals. It is generally present in deuterostomes (vertebrates, etc.), but in protostomes (arthropods, molluscs, flatworms, nematodes, annelids, etc.) it is replaced by octopamine, a closely related chemical with a closely related synthesis pathway. In insects, octopamine has alerting and activating functions that correspond (at least roughly) with the functions of norepinephrine in vertebrates. It has been argued that octopamine evolved to replace norepinephrine rather than vice versa; however, the nervous system of amphioxus (a primitive chordate) has been reported to contain octopamine but not norepinephrine, which presents difficulties for that hypothesis.
== Toxicity == Some of the same properties that make nanoparticles efficient drug carriers also contribute to their toxicity. For example, gold nanoparticles are known to interact with proteins through surface adsorption, forming a protein corona, which can be utilized for cargo loading and immune shielding. However, this protein-adsorption property can also disrupt normal protein function that is essential for homeostasis, especially when the protein contains exposed sulfur groups. The photothermal effect, which can be induced to kill tumor cells, may also create reactive oxygen species that impose oxidative stress on surrounding healthy cells. Gold nanoparticles of sizes below 4-5 nm fit in DNA grooves which can interfere with transcription, gene regulation, replication, and other processes that rely on DNA-protein binding. Lack of biodegradability for some nanoparticle chemistries can lead to accumulation in certain tissues, thus interfering with a wide range of biological processes. Currently, there is no regulatory framework in the United States for testing nanoparticles for their general impact on health and on the environment.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.